

FOR IMMEDIATE RELEASE

Media Contacts:

VentriPoint Media Contacts:

Russo Partners LLC
Ian Stone
(619) 814-3510
ian.stone@russopartnersllc.com

**VentriPoint Diagnostics Files Management Discussion and
Analysis, Unaudited Financial Results**

***Acquisition of images for Two Additional Knowledge Based Reconstruction
Databases Highlights of Management Discussion and Analysis***

SEATTLE, June 2, 2008 – VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (MD&A), as well as its unaudited financial results for the three months ended March 31, 2008, with the Canadian Securities Administrators through the SEDAR filing system.

Development Highlights

In its MD&A, VentriPoint describes that, subject to image processing and validation testing, it has received enough images to populate its disease specific database used to complete Knowledge Based Reconstruction for patients impacted by two additional diseases. These disease states, systemic right ventricle and right ventricle to pulmonary artery conduit, will be the second and third databases, respectively, of four that comprise the first commercial offering of the VentriPoint Diagnostic System. The company anticipates that validation testing will commence by July 1, 2008, and August 1, 2008, respectively.

“As we describe in the MD&A, the completion of these database are substantial milestones as we move closer to the first commercial offering of the VentriPoint Diagnostic System,” said Joseph Ashley, CEO of VentriPoint Diagnostics. “These databases will be referenced as the System creates accurate reconstructions

and measurements of disease impacted hearts in a rapid, cost effective manner that is not available today.”

Financial Highlights

In its unaudited financial results, VentriPoint reported a consolidated net loss of \$892,931 for the three months ended March 31, 2008, or \$0.02 per share compared to a net loss of \$219,732, or \$0.02 per share for the three months ended March 31, 2007. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.

For the three months ended March 31, 2008, research and development expenses totaled \$536,226, compared to \$137,676 for the three months ended March 31, 2007. The largest research and development expense for the three months ended March 31, 2008 was payroll costs to build a highly qualified research and development team.

VentriPoint reported a foreign exchange loss of \$108,863 as the result of a change in the currency exchange rate used to translate Canadian monetary items into the US dollar on the date of translation of March 31, 2008.

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon technology received by VentriPoint through its technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

###